Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
A phase 2 trial of Tucatinib, Trastuzumab, CAPOX in gallbladder cancer, run by Seagen, a wholly owned subsidiary of Pfizer, active and no longer recruiting.
Overview
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers is a phase 2 interventional study registered as NCT04430738 by Seagen, a wholly owned subsidiary of Pfizer, with 40 participants enrolled, started 2020-09-15 and due to reach its primary completion in 2024-07-31. Interventions recorded: tucatinib, trastuzumab, oxaliplatin, leucovorin, fluorouracil. Conditions listed: Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)
Shares Tucatinib, Capecitabine, Trastuzumab, Pfizer (incl. Seagen).
- TrialA Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Fluorouracil (5-FU), Capecitabine.
- TrialGivastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Capecitabine.
- TrialBOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Fluorouracil (5-FU).
- TrialA Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Fluorouracil (5-FU).
- TrialA Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil,
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Fluorouracil (5-FU).
- TrialA Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin), Capecitabine.
- TrialPhase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), CAPOX (capecitabine, oxaliplatin).